Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis.
Luigjes-Huizer YL, Tauber NM, Humphris G, Kasparian NA, Lam WWT, Lebel S, Simard S, Smith AB, Zachariae R, Afiyanti Y, Bell KJL, Custers JAE, de Wit NJ, Fisher PL, Galica J, Garland SN, Helsper CW, Jeppesen MM, Liu J, Mititelu R, Monninkhof EM, Russell L, Savard J, Speckens AEM, van Helmondt SJ, Vatandoust S, Zdenkowski N, van der Lee ML. Luigjes-Huizer YL, et al. Among authors: zdenkowski n. Psychooncology. 2022 Jun;31(6):879-892. doi: 10.1002/pon.5921. Epub 2022 Apr 7. Psychooncology. 2022. PMID: 35388525 Free PMC article. Review.
Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.
Wilcken N, Zdenkowski N, White M, Snyder R, Pittman K, Mainwaring P, Green M, Francis P, De Boer R, Colosimo M, Chua S, Chirgwin J, Beith J, Bell R. Wilcken N, et al. Among authors: zdenkowski n. Asia Pac J Clin Oncol. 2014 Jun;10 Suppl S4:1-14. doi: 10.1111/ajco.12206. Asia Pac J Clin Oncol. 2014. PMID: 24797445 Review.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M. Mayer EL, et al. Among authors: zdenkowski n. Lancet Oncol. 2021 Feb;22(2):212-222. doi: 10.1016/S1470-2045(20)30642-2. Epub 2021 Jan 15. Lancet Oncol. 2021. PMID: 33460574 Clinical Trial.
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Mann GB, Coates AS, Gebski V, Davies L, Thornton R, Reaby L, Cuzick J, Green M; Australia and New Zealand Breast Cancer Trials Group. Zdenkowski N, et al. Ann Oncol. 2016 May;27(5):806-12. doi: 10.1093/annonc/mdw055. Epub 2016 Feb 9. Ann Oncol. 2016. PMID: 26861603 Free article. Clinical Trial.
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, Kannourakis G, Francis PA, Chirgwin J, Abdi E, Gebski V, Veillard AS, Zannino D, Wilcken N, Reaby L, Lindsay DF, Badger HD, Forbes JF; Australia and New Zealand Breast Cancer Trials Group. McCarthy N, et al. Among authors: zdenkowski n. Breast. 2014 Apr;23(2):142-51. doi: 10.1016/j.breast.2013.12.001. Epub 2014 Jan 3. Breast. 2014. PMID: 24393617 Free article. Clinical Trial.
46 results